Lytix Biopharma is a clinical-stage company committed to developing novel immunotherapy for cancer patients. The aim is to become a leader within immunotherapy of solid tumors.
Lytix Biopharma’s development program focuses on immunological activation of solid tumors such as breast cancer, malignant melanoma, sarcoma, head & neck, and other. The mode of action is to release antigens and reshape the tumor microenvironment and as such turning cold tumors hot.
The strategy is to develop the oncolytic peptides within several tumor type indications, and also explore several therapeutic settings such as combination therapies and T-cell therapies.